ESTRO 2021 Abstract Book

S111

ESTRO 2021

Conclusion Data from the BC2001 trial suggest that female patients treated with (chemo)radiotherapy for localised bladder cancer report a worse quality of life and toxicity during follow up. This disparity resolves by 5 years post treatment. OC-0179 Associations between patient-reported outcomes and radiation dose in brain tumour patients. L. Haldbo-Classen 1 , A. Amidi 2 , L. Wu 3 , S. Lukacova 1 , G.V. Oettingen 4 , Y. Lassen-Ramshad 5 , R. Zachariae 6 , J.F. Kallehauge 5 , M. Høyer 5 1 Aarhus University Hospital, Oncology, Aarhus, Denmark; 2 Aarhus University, Psychology and Behavioural Sciences and Unit for Psychooncology and Health Psychology, Aarhus, Denmark; 3 Aarhus University, Aarhus Institute of Advanced Studies, Aarhus, Denmark; 4 Aarhus University Hospital, Neurosurgery, Aarhus, Denmark; 5 Aarhus University Hospital, Danish Center for Particle Therapy, Aarhus, Denmark; 6 Aarhus University, Psychology and Behavioural Sciences and Unit for Psychooncology and Health Psychology, Aarhus, Denmark Purpose or Objective We previously reported that high radiation doses to left-sided hippocampus, temporal lobe, frontal lobe, thalamus, and total brain correlated with impaired verbal learning and memory, verbal fluency, executive function, and processing speed in patients with a primary non-glioblastoma brain tumour treated with radiation therapy (RT). Here, we explore associations between radiation dose and patient-reported health- related quality-of-life (HRQoL) and cognitive function assessed by the Patient’s Assessment of Own Functioning Inventory (PAOFI). Materials and Methods In this cross-sectional study, 78 patients who had received RT for a primary brain tumour, underwent neuropsychological testing and completed questionnaires on HRQoL, cognitive function, cancer-related fatigue, depression, anxiety and perceived stress. This study focuses on the patient-reported outcomes. Associations between patient-reported HRQoL, patient-reported cognitive function (memory, language and higher level of cognitive function) and radiation doses to total brain, brainstem, hippocampus, thalamus, temporal lobes and frontal lobes were explored. In addition, we analysed correlations between neuropsychological test scores and patient-reported cognitive function. Results The median time between RT and testing was 4.6 years (range 1-9). Bases on outcomes on HRQoL and PAOFI, patients were dichotomized into an “impaired group” (patients with the poorest score) or an “unimpaired group” (patients with better scores). Patients in the “impaired HRQoL group” had received higher mean radiation doses to the total brain ( p =0.04), brainstem ( p =0.01) and hippocampus ( p =0.01). Poor score on patient-reported higher level of cognitive functioning were associated with high mean doses to the total brain ( p =0.02), brainstem ( p =0.03), hippocampus ( p <0.01), temporal lobes ( p <0.01) and thalamus ( p =0.01). See figure 1. Patient-reported cognitive function correlated well with objective neuropsychological tests High radiation doses to specific brain structures were associated with impaired HRQoL and patient-reported cognitive function with potentially negative implications to patients’ daily living. Patient-reported outcome on HRQoL and PAOFI and their associations with radiation doses to the brain and its sub-structures may provide important information on radiation tolerance to the brain and sub-structures. These findings require further validation in prospective trials with pre-treatment assessment. outcomes. Conclusion